Example: Heart Attack

Search clinical trials for: 4-Aminopyridine

Total 64 results

NCT03899584

Active, not recruiting

High Doses of 4-aminopyridine in Clinically Complete Chronic Spinal Cord Injury Patients.

Conditions: Spinal Cord Injuries; Chronic
NCT02280096

Completed

Efficacy and Safety of 4-aminopyridine on Cognitive Performance and Motor Function of Patients With Multiple Sclerosis

Conditions: Multiple Sclerosis
NCT03701581

Active, not recruiting

4-aminopyridine Treatment for Nerve Injury

Conditions: Nerve Injury; Prostate Cancer
NCT02868567

Recruiting

Use of Dalfampridine in Primary Lateral Sclerosis

Conditions: Motor Neuron Disease, Upper
NCT01337986

Completed

Ampyra for Optic Neuritis in Multiple Sclerosis

Conditions: Multiple Sclerosis; Optic Neuritis
NCT03658408

Withdrawn

4-aminopyridine Treatment for Nerve Injury From Radical Retro-Pubic Prostatectomy

Conditions: Prostate Disease
NCT02422940

Terminated

Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of Dalfampridine.

Conditions: Post-ischemic Stroke
NCT01535664

Completed

An Open Label, Proof of Concept Study to Evaluate the Effects of Dalfampridine Withdrawal on Gait and Balance Parameters in Subjects With Multiple Sclerosis (MS)

Conditions: Multiple Sclerosis
NCT01645787

Completed

Short and Long Term Treatment With 4-AP in Ambulatory SMA Patients

Conditions: Spinal Muscular Atrophy
NCT04148781

Not yet recruiting

Fampridine-SR and Optic Neuritis Recovery

Conditions: Optic Neuritis
NCT02166346

Completed

Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch)

Conditions: Transverse Myelitis; Neuromyelitis Optica; Idiopathic Transverse Myelitis; Myelitis NOS
NCT01811706

Completed

Dalfampridine and Gait in Spinocerebellar Ataxias

Conditions: Spinocerebellar Ataxias Type 1; Spinocerebellar Ataxias Type 2; Spinocerebellar Ataxias Type 3; Spinocerebellar Ataxias Type 6
NCT01621113

Completed

Combination Therapy With Dalfampridine and Locomotor Training for Chronic, Motor Incomplete Spinal Cord Injury

Conditions: Spinal Cord Injury
NCT01215084

Completed

A Pharmacokinetics (PK) and Safety Study of Oral Fampridine-PR 10 mg in Chinese, Japanese, and Caucasian Adult Healthy Volunteers

Conditions: Healthy
NCT02219932

Completed

Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis

Conditions: Multiple Sclerosis
NCT01576354

Unknown status

Characterization of the Effects of Prolonged-release Fampridine on Ambulatory Function in Patients With Multiple Sclerosis

Conditions: Multiple Sclerosis
NCT01356940

Completed

A Placebo Controlled Trial of Dalfampridine ER for Ambulatory Activity in People With Multiple Sclerosis

Conditions: Multiple Sclerosis
NCT01975324

Completed

A New Medicine to Treat Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)

Conditions: Non Arteritic Ischemic Optic Neuropathy
NCT02849782

Completed

Short and Long Term Multiple Outcomes in Persons With Multiple Sclerosis Treated by Fampridine.

Conditions: Multiple Sclerosis
NCT02271217

Completed

A Study to Evaluate the Efficacy and Safety of Two Dose Strengths of Dalfampridine Extended Release Tablets.

Conditions: Post-Ischemic Stroke
NCT01480076

Completed

Open-Label Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) on Quality of Life as Reported by Participants With Multiple Sclerosis

Conditions: Multiple Sclerosis
NCT00483652

Completed

Study of Fampridine-SR Tablets in Multiple Sclerosis Patients

Conditions: Multiple Sclerosis
NCT01444300

Completed

Dalfampridine for Imbalance in Multiple Sclerosis

Conditions: Multiple Sclerosis; Fatigue
NCT00649792

Completed

Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis Who Participated in the MS-F204 Trial

Conditions: Multiple Sclerosis
NCT00648908

Completed

Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR Tablets in Multiple Sclerosis Patients Who Participated in the MS-F203 Trial

Conditions: Multiple Sclerosis